Meeting
2013 Genitourinary Cancers Symposium
Serum IGF-1 levels are decreased in men with advanced prostate cancer treated with the ERα agonist, gtx-758.
Authors
Evan Y. Yu
Fred Hutchinson Cancer Research Center, Seattle, WA
Evan Y. Yu , Marc Gittelman , Thomas E. Keane , Ronald Tutrone , Laurence Belkoff , Robert Given , Joel Bass , Franklin Chu , Mike Gambla , Franklin Gaylis , James Bailen , Robert H. Getzenberg , Christopher Coss , Michael L. Hancock , James T. Dalton , Mitchell S. Steiner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01326312
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 171)
DOI
10.1200/jco.2013.31.6_suppl.171
Abstract #
171
Poster Bd #
L4
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
Rate of hot flashes in patients with advanced prostate cancer treated with GTx-758.
First Author: Evan Y. Yu
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world experience on tolerability and safety of relugolix combined with androgen signaling inhibitors in patients with advanced prostate cancer.
First Author: Jian Guan
Poster
2024 ASCO Genitourinary Cancers Symposium
Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer.
First Author: Nicholas George Nickols
Poster
2013 Genitourinary Cancers Symposium
Effect of Gtx-758, an ERα agonist, on serum-free testosterone and serum PSA in men with advanced prostate cancer.
First Author: Evan Y. Yu